We think that a practical application of our proposal is a stable magnetic PSMA radiobioconjugate labeled with 44Sc and 47Sc, which according to the in vivo studies, can be used for aggressive prostate cancer. The gene discussed is FOLH1; the disease is prostate carcinoma.